JP2010523678A - 凍結乾燥薬学的組成物、及びその製造及び使用方法 - Google Patents

凍結乾燥薬学的組成物、及びその製造及び使用方法 Download PDF

Info

Publication number
JP2010523678A
JP2010523678A JP2010503077A JP2010503077A JP2010523678A JP 2010523678 A JP2010523678 A JP 2010523678A JP 2010503077 A JP2010503077 A JP 2010503077A JP 2010503077 A JP2010503077 A JP 2010503077A JP 2010523678 A JP2010523678 A JP 2010523678A
Authority
JP
Japan
Prior art keywords
lyophilized solid
api
solid formulation
formulation
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523678A5 (enExample
Inventor
ドゥルー、クレアー
ダーフィー、スティーブ、エル．
ホール、リチャード、ジェイ．
グエン、タム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon France SAS
Original Assignee
Cephalon France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon France SAS filed Critical Cephalon France SAS
Publication of JP2010523678A publication Critical patent/JP2010523678A/ja
Publication of JP2010523678A5 publication Critical patent/JP2010523678A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010503077A 2007-04-11 2008-04-11 凍結乾燥薬学的組成物、及びその製造及び使用方法 Pending JP2010523678A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290443A EP1980240A1 (en) 2007-04-11 2007-04-11 Lyophilized pharmaceutical compositions and methods of making and using same
PCT/US2008/004755 WO2008127679A1 (en) 2007-04-11 2008-04-11 Lyophilized pharmaceutical compositions and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014165583A Division JP2015028030A (ja) 2007-04-11 2014-08-15 凍結乾燥薬学的組成物、及びその製造及び使用方法

Publications (2)

Publication Number Publication Date
JP2010523678A true JP2010523678A (ja) 2010-07-15
JP2010523678A5 JP2010523678A5 (enExample) 2012-06-14

Family

ID=38477086

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010503077A Pending JP2010523678A (ja) 2007-04-11 2008-04-11 凍結乾燥薬学的組成物、及びその製造及び使用方法
JP2014165583A Pending JP2015028030A (ja) 2007-04-11 2014-08-15 凍結乾燥薬学的組成物、及びその製造及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014165583A Pending JP2015028030A (ja) 2007-04-11 2014-08-15 凍結乾燥薬学的組成物、及びその製造及び使用方法

Country Status (5)

Country Link
EP (2) EP1980240A1 (enExample)
JP (2) JP2010523678A (enExample)
CA (1) CA2683603A1 (enExample)
MX (1) MX2009010989A (enExample)
WO (1) WO2008127679A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535613A (ja) * 2014-11-21 2017-11-30 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールの舌下製剤
JP2022533510A (ja) * 2019-03-12 2022-07-25 エデンブリッジ・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー グリコピロレートを含む口腔内崩壊錠剤および生物学的利用率を増大させるための方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2359812A1 (en) * 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
WO2011121496A1 (en) 2010-03-31 2011-10-06 Wockhardt Limited Composition comprising insulin and herbal oil for transdermal or transmucosal administration
GB201007290D0 (en) * 2010-04-30 2010-06-16 R5 Pharmaceuticals Ltd Pharmaceutical powder compositions
CN102440956B (zh) * 2011-12-21 2013-06-05 中国人民解放军第三军医大学 自乳化舒马曲坦及其盐制剂的制备方法
FR2987267B1 (fr) * 2012-02-28 2015-01-16 Debregeas Et Associes Pharma Application du modafinil dans le traitement de substitution des cacainomanes
GR20120100181A (el) * 2012-03-28 2013-10-15 Μαριαννα Αχιλλεα Παπαμιχαηλ Νεες λυοφιλοποιημενες φαρμακοτεχνικες και καλυντικοτεχνικες μορφες λυοφιλοποιημενων γαλακτωματων
US20150209275A1 (en) * 2012-09-11 2015-07-30 University Of The Witwatersrand, Johannesburg Fast Dissolving Ocular Insert
WO2017072774A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008A (en) * 1847-03-13 Machinery for cleaning
JP2004534839A (ja) * 2001-07-10 2004-11-18 シーマ・ラブス、インコーポレイテッド 連続的薬剤送達システム
WO2005077336A1 (en) * 2004-02-12 2005-08-25 Korea Institute Of Science And Technology Composition and formulation of colloidal system comprising biocompatible aqueous-soluble polymer, and preparation method thereof
JP2005526021A (ja) * 2002-01-31 2005-09-02 ナショナル スターチ アンド ケミカル インベストメント ホールディング コーポレイション 多糖とポリカルボキシル化ポリマーとを含んでなる生物接着性組成物
JP2006512409A (ja) * 2002-10-31 2006-04-13 ユーエムディー， インコーポレイテッド 薬物送達用治療組成物で被覆上皮に対するもの及びそれを介するもの
WO2007034287A2 (en) * 2005-09-19 2007-03-29 University Of The Witwatersrand, Johannesburg Oramucosal pharmaceutical dosage form

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039836A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
WO2006103657A2 (en) * 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008A (en) * 1847-03-13 Machinery for cleaning
JP2004534839A (ja) * 2001-07-10 2004-11-18 シーマ・ラブス、インコーポレイテッド 連続的薬剤送達システム
JP2005526021A (ja) * 2002-01-31 2005-09-02 ナショナル スターチ アンド ケミカル インベストメント ホールディング コーポレイション 多糖とポリカルボキシル化ポリマーとを含んでなる生物接着性組成物
JP2006512409A (ja) * 2002-10-31 2006-04-13 ユーエムディー， インコーポレイテッド 薬物送達用治療組成物で被覆上皮に対するもの及びそれを介するもの
WO2005077336A1 (en) * 2004-02-12 2005-08-25 Korea Institute Of Science And Technology Composition and formulation of colloidal system comprising biocompatible aqueous-soluble polymer, and preparation method thereof
WO2007034287A2 (en) * 2005-09-19 2007-03-29 University Of The Witwatersrand, Johannesburg Oramucosal pharmaceutical dosage form

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535613A (ja) * 2014-11-21 2017-11-30 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールの舌下製剤
JP2021001173A (ja) * 2014-11-21 2021-01-07 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールの舌下製剤
JP2022533510A (ja) * 2019-03-12 2022-07-25 エデンブリッジ・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー グリコピロレートを含む口腔内崩壊錠剤および生物学的利用率を増大させるための方法

Also Published As

Publication number Publication date
CA2683603A1 (en) 2008-10-23
EP1980240A1 (en) 2008-10-15
WO2008127679A1 (en) 2008-10-23
EP2152234A1 (en) 2010-02-17
MX2009010989A (es) 2009-10-29
JP2015028030A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
EP1980245A1 (en) Bilayer lyophilized pharmaceutical compositions and methods of making and using same
JP2015028030A (ja) 凍結乾燥薬学的組成物、及びその製造及び使用方法
US20100080829A1 (en) Lyophilized pharmaceutical compositions and methods of making and using same
US10420763B2 (en) Sublingual apomorphine
JP2001510785A (ja) 速崩壊性口内溶解錠の製造に適した顆粒の製造方法
US20080031947A1 (en) Orally dissolvable/disintegrable lyophilized dosage forms containing protected
Gupta et al. An overview of novel techniques employed in mouth dissolving drug delivery system
Dave et al. A review on promising novel drug delivery system-bioadhesive drug delivery system
Sharma et al. Thermoreversible insitu gel for nasal drug delivery
GAUTAM et al. Formulation Aspects and Manufacturing Technology–A Review on Fast Disintegrating Tablets
Raval et al. Journal of Drug Discovery and Therapeutics 1 (3) 2013, 49-56
Bhasin et al. Advances in Formulation of Orally Disintegrating Dosage Forms: A
HK1218630B (en) Sublingual apomorphine
HK40000118A (en) Sublingual apomorphine
EP1905429A1 (en) Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130716

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130815

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140815

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140826

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141121